MedPath

Theratechnologies

Ownership
-
Employees
58
Market Cap
-
Website
Introduction

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Clinical Trials

9

Active:9
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

2

FDA:2

Drug Approvals

EGRIFTA SV

Approval Date
Feb 29, 2024
FDA

TROGARZO

Approval Date
Dec 20, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.